AC Immune (NASDAQ:ACIU) announced positive interim safety and immunogenicity data from its Phase 2 VacSYn clinical trial, evaluating ACI-7104.056 as a treatment for patients with early Parkinson’s disease.
The company reported that interim findings demonstrated that positive antibody responses were effectively induced against the target antigen by week six following two immunizations and showed significant boostability. Treatment with ACI-7104.056 induced an increase in anti-a-syn antibodies on average 16-fold higher than the placebo background level after three immunizations.
“We are encouraged by these initial Phase 2 safety and immunogenicity data on our ACI-7104.056 active immunotherapy being studied in early Parkinson’s disease,” said Dr. Andrea Pfeifer, CEO of AC Immune SA.
“The level of immunogenicity after only three months of treatment as well as the continued positive safety profile, reinforces the best-in-class characteristics of our clinically validated anti-a-syn active immunotherapy for the treatment of Parkinson’s disease. We look forward to sharing further updates in H1 2025 including the decision to expand into Part 2 of the VacSYn study,” Dr. Pfeifer added.
